Takhzyro
lanadelumab
APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaRare Disease
Launch2018-08-23
US LOE2034-01-01
Peak Sales Est$2000M
Formulations[{"id":"takhzyro-sc","route":"SC","device":"Pre-filled syringe","setting":"PATIENT_SELF","frequency"
Companies
TAK (ORIGINATOR)100%
Mechanism: Plasma kallikrein inhibitor
Expert: Monoclonal antibody targeting plasma kallikrein, preventing bradykinin generation and subsequent angioedema attacks.
Everyday: Blocks a protein that causes swelling attacks in hereditary angioedema.
Targets: ["KLKB1"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2024 | $1,470M |
| Q1 2025 | $380M |
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| HAE proph | APPROVED | HELP | [{"stage":"APPROVED","region":"US","approval_date":"2018-08-23"},{"stage":"APPRO |
Notes
Leading prophylactic therapy for HAE. Every 2-week SC dosing. ~6,700 patients treated worldwide. Growing mid-single digits.
Data from Supabase · Updated 2026-03-24